Linked Life Data

6547268

Source:http://linkedlifedata.com/resource/pubmed/id/6547268

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1984-6-27
pubmed:abstractText
Thirty-eight patients with advanced or recurrent epithelial ovarian cancer no longer amenable to management with surgery, radiotherapy, or chemotherapy with known activity were given piperazinedione 9 mg/m2 intravenously every 3 weeks. Of the 31 patients evaluable for response, only one achieved a partial response of disease (3%), while there were no complete responses. Fourteen (45%) experienced progression of disease less than 1 month after starting therapy. Adverse effects consisted primarily of myelosuppression (81%), nausea and vomiting (32%), and azotemia (29%) with three patients (10%) having life-threatening thrombocytopenia. While adverse effects were tolerated, the drug at the dose and schedule tested has only minimal activity at best and should not be considered for further trials in epithelial ovarian cancer.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0277-3732
pubmed:author
pubmed:issnType
Print
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
261-3
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1984
pubmed:articleTitle
Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary. A Gynecologic Oncology Group study.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.